- Home
- BLNE vs EDSA Comparison
BLNE vs EDSA Comparison
Compare BLNE & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNE
- EDSA
- Stock Information
- Founded
- BLNE 2019
- EDSA 2015
- Country
- BLNE United States
- EDSA Canada
- Employees
- BLNE N/A
- EDSA N/A
- Industry
- BLNE
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- BLNE
- EDSA Health Care
- Exchange
- BLNE NYSE
- EDSA Nasdaq
- Market Cap
- BLNE 11.9M
- EDSA 13.8M
- IPO Year
- BLNE N/A
- EDSA N/A
- Fundamental
- Price
- BLNE $1.34
- EDSA $2.05
- Analyst Decision
- BLNE
- EDSA Strong Buy
- Analyst Count
- BLNE 0
- EDSA 2
- Target Price
- BLNE N/A
- EDSA $13.00
- AVG Volume (30 Days)
- BLNE 5.7M
- EDSA 33.4K
- Earning Date
- BLNE 08-13-2025
- EDSA 08-08-2025
- Dividend Yield
- BLNE N/A
- EDSA N/A
- EPS Growth
- BLNE N/A
- EDSA N/A
- EPS
- BLNE N/A
- EDSA N/A
- Revenue
- BLNE $5,213,000.00
- EDSA N/A
- Revenue This Year
- BLNE $456.73
- EDSA N/A
- Revenue Next Year
- BLNE $28.26
- EDSA N/A
- P/E Ratio
- BLNE N/A
- EDSA N/A
- Revenue Growth
- BLNE 63.03
- EDSA N/A
- 52 Week Low
- BLNE $0.62
- EDSA $1.55
- 52 Week High
- BLNE $29.80
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- BLNE N/A
- EDSA 52.89
- Support Level
- BLNE N/A
- EDSA $1.91
- Resistance Level
- BLNE N/A
- EDSA $2.14
- Average True Range (ATR)
- BLNE 0.00
- EDSA 0.12
- MACD
- BLNE 0.00
- EDSA 0.02
- Stochastic Oscillator
- BLNE 0.00
- EDSA 64.52
About BLNE EASTSIDE DISTILLING INC
Beeline Holdings Inc is a technology-driven mortgage lender and title provider building a fully digital, AI-powered platform that simplifies and accelerates the home financing process.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.